Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: Relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment

Atherosclerosis

Volumn 196, Issue 2, 2008, Pages 931-936

  Iwase, Masanori ^a   Sonoki, Kazuo ^a   Sasaki, Nobuhiro ^a   Ohdo, Shigehiro ^b   Higuchi, Shun ^b   Hattori, Hiroaki ^c   Iida, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c BML   (Japan)

Author keywords

Diabetic nephropathy; Diabetic retinopathy; Hyperlipidemia; Oxidative stress; Oxidized LDL; Statin

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; CHEMOKINE; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; SIMVASTATIN;

ADULT; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ELECTROSPRAY MASS SPECTROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIQUID CHROMATOGRAPHY; MALE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; LYSOPHOSPHATIDYLCHOLINES; MALE; MIDDLE AGED; SIMVASTATIN;

EID: 38349186592     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.02.012     Document Type: Article

References (26)

1. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes 54 (2005) 1615-1625
2. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 272 (1997) 20963-20966
3. Steinbrecher U.P., and Pritchard P.H. Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase. J Lipid Res 30 (1989) 305-315
4. Hurt-Camejo E., Camejo G., Peilot H., Oorni K., and Kovanen P. Phospholipase A(2) in vascular disease. Circ Res 89 (2001) 298-304
5. Quinn M.T., Parthasarathy S., and Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA 85 (1988) 2805-2809
6. Kume N., and Gimbrone Jr. M.A. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest 93 (1994) 907-911
7. Zalewski A., and Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 25 (2005) 923-931
8. Sobenin I.A., Tertov V.V., Koschinsky T., et al. Modified low density lipoprotein from diabetic patients causes cholesterol accumulation in human intimal aortic cells. Atherosclerosis 100 (1993) 41-54
9. Takahara N., Kashiwagi A., Nishio Y., et al. Oxidized lipoproteins found in patients with NIDDM stimulate radical-induced monocyte chemoattractant protein-1 mRNA expression in cultured human endothelial cells. Diabetologia 40 (1997) 662-670
10. Shi A.H., Yoshinari M., Wakisaka M., Iwase M., and Fujishima M. Lysophosphatidylcholine molecular species in low density lipoprotein of type 2 diabetes. Horm Metab Res 31 (1999) 283-286
11. Sonoki K., Iwase M., Iino K., et al. Atherogenic role of lysophosphatidylcholine in low-density lipoprotein modified by phospholipase A2 and in diabetic patients: protection by nitric oxide donor. Metabolism 52 (2003) 308-314
12. Packard C.J., O'Reilly D.S., Caslake M.J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 343 (2000) 1148-1155
13. O'Donoghue M., Morrow D.A., Sabatine M.S., et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 113 (2006) 1745-1752
14. Eisaf M., and Tselepis A.D. Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis. Biochem Pharmacol 66 (2003) 2069-2073
15. Winkler K., Abletshauser C., Friedrich I., Hoffmann M.M., Wieland H., and Marz W. Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes. J Clin Endocrinol Metab 89 (2004) 1153-1159
16. Albert M.A., Glynn R.J., Wolfert R.L., and Ridker P.M. The effect of statin therapy on lipoprotein associated phospholipase A2 levels. Atherosclerosis 182 (2005) 193-198
17. Schaefer E.J., McNamara J.R., Asztalos B.F., et al. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol 95 (2005) 1025-1032
18. Sonoki K., Yoshinari M., Iwase M., et al. Glycoxidized low-density lipoprotein enhances monocyte chemoattractant protein-1 mRNA expression in human umbilical vein endothelial cells. Relation to lysophosphatidylcholine contents and inhibition by nitric oxide donor. Metabolism 51 (2002) 1135-1142
19. Kujiraoka T., Iwasaki T., Ishihara M., et al. Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus. J Lipid Res 44 (2003) 2006-2014
20. Karasawa K., Harada A., Satoh N., Inoue K., and Setaka M. Plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res 42 (2003) 93-114
21. Noto H., Chitkara P., and Raskin P. The role of lipoprotein-associated phospholipase A2 in the metabolic syndrome and diabetes. J Diab Complications 20 (2006) 343-348
22. Zhu Q., McMaster J., Mymin D., et al. Effects of atorvastatin treatment on the oxidatively modified low density lipoprotein in hyperlipidemic patients. Mol Cell Biochem 207 (2000) 9-17
23. 2+ sensitivity in alpha-toxin-permeabilized small mesenteric artery from the rat. Br J Pharmacol 117 (1996) 1238-1244
24. Chen L., Liang B., Froese D.E., et al. Oxidative modification of low density lipoprotein in normal and hyperlipidemic patients. Effect of lysophosphatidylcholine composition on vascular relaxation. J Lipid Res 38 (1997) 546-553
25. Nakano T., Raines E.W., Abraham J.A., Klagsbrun M., and Ross R. Lysophosphatidylcholine upregulates the level of heparin-binding epidermal growth factor-like growth factor mRNA in human monocytes. Proc Natl Acad Sci USA 91 (1994) 1069-1073
26. Boyd H.F., Fell S.C., Hickey D.M., et al. Potent, orally active inhibitors of lipoprotein-associated phospholipase A(2): 1-(biphenylmethylamidoalkyl)-pyrimidones. Bioorg Med Chem Lett 12 (2002) 5155